High-Level Resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4)
Author(s) -
Stephanie M. Hamilton,
J. Andrew N. Alexander,
Eun Ju Choo,
Li Basuino,
Thaina Miranda da Costa,
Anatoly Severin,
Marilyn Chung,
Sandra Aedo,
N.C.J. Strynadka,
Alexander Tomasz,
Som S. Chatterjee,
Henry F. Chambers
Publication year - 2017
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02727-16
Subject(s) - penicillin binding proteins , microbiology and biotechnology , staphylococcus aureus , mutant , cephalosporin , penicillin , antibiotics , peptidoglycan , biology , methicillin resistant staphylococcus aureus , cell wall , bacteria , biochemistry , gene , genetics
Penicillin-binding protein 4 (PBP4), a nonessential, low-molecular-weight penicillin-binding protein ofStaphylococcus aureus , has been implicated in low-level resistance to β-lactam antibiotics, although the mechanism is unknown. Mutations in PBP4 and its promoter were identified in a laboratory-generated mutant strain, CRB, which expresses high-level resistance to β-lactams, including resistance to the new-generation cephalosporins active against methicillin-resistant strains ofS. aureus . These mutations did not appreciably alter the β-lactam antibiotic binding affinity of purified recombinant mutant PBP4 compared to that of wild-type PBP4. Compared to the susceptible parent strain, COLnex, the CRB strain produces a highly cross-linked cell wall peptidoglycan, indicative of increased transpeptidase activity. Thepbp4 promoter mutation of CRB was associated with greatly increased amounts of PBP4 in membranes compared to those in the COLnex parent. Replacement of the native promoter of COLnex with the mutant promoter of CRB resulted in increased amounts of PBP4 in membranes and a highly cross-linked cell wall. PBP4 can be repurposed to provide essential transpeptidase activityin vivo and confer high-level resistance to β-lactam antibiotics, such as ceftobiprole and ceftaroline.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom